SEMI
发表于 2025-3-23 10:24:47
http://reply.papertrans.cn/87/8608/860732/860732_11.png
暂时休息
发表于 2025-3-23 17:23:13
http://reply.papertrans.cn/87/8608/860732/860732_12.png
squander
发表于 2025-3-23 19:16:13
http://reply.papertrans.cn/87/8608/860732/860732_13.png
磨碎
发表于 2025-3-23 22:32:25
Convenient Sample Size Formula,ple size formula with associated numerical tables for sizing clinical trials with multiple co-primary endpoints. We provide numerical examples to illustrate use of the formula and associated tables, and provide the programming codes for the R and SAS software packages.
下边深陷
发表于 2025-3-24 03:46:42
Further Developments,elopments for designing randomized trials with other design characteristics including: (i) other inferential goals, (ii) more than two intervention groups, (iii) group sequential designs, and (iv) endpoints with other measurement scales such as time to-event.
Heresy
发表于 2025-3-24 09:04:45
Binary Co-primary Endpoints,l method with and without a continuity correction, the arcsine method with and without a continuity correction, and the Fisher’s exact method. We evaluate the behavior of the sample size and empirical power associated with the methods. We also provide numerical examples to illustrate the methods.
抛射物
发表于 2025-3-24 10:59:56
http://reply.papertrans.cn/87/8608/860732/860732_17.png
Endometrium
发表于 2025-3-24 15:50:04
Book 2015 multiple primary or co-primary, offering an important reference work for statisticians working in this area..The determination of sample size and the evaluation of power are fundamental and critical elements in the design of clinical trials. If the sample size is too small, important effects may go
BLAZE
发表于 2025-3-24 19:53:21
Introduction,apture a more complete characterization of the intervention effects and provide more informative intervention comparisons. For these reasons, use of more than one primary endpoint has become a common design feature in clinical trials for disease areas such as oncology, infectious disease, and cardio
Indelible
发表于 2025-3-25 01:21:07
Continuous Co-primary Endpoints,interventions with multiple co-primary continuous endpoints in a clinical trial. We provide numerical examples to illustrate the methods and introduce conservative sample sizing strategies for these clinical trials.